Clinical Trial

Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance: a Phase II Clinical Study

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.The study is divided into two parts. The main objective of part I is to assess the efficacy and safety of JSKN016 in selected subjects with advanced non-small cell lung cancer. The main objective of part II is to compare the efficacy of JSKN016 and docetaxel in subjects with advanced non-small cell lung cancer.
Trial Details
NCT Number NCT06775483
Lead Sponsor Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Conditions Advanced Non-small Cell Lung Cancer
Enrollment 220 participants
Start Date 2025-01-17
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-15